Evidence map›Paper›PMID 39806972›Full record

ReviewCurrent topics in medicinal chemistry2025

Traditional Chinese Medicine for Liver Cancer Treatment: Network Pharmacology Research.

Shihao Zheng, Yixiao Gu, Wenying Qi, Wei Wang, Xiaoke Li, Xiaobin Zao, Size Li, Shaoyu Liu, Tianyu Xue, Yongan Ye and 1 more

Abstract readReview
In one paragraph

Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Recent Advances in the Mechanisms and Applications ofMolecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shihao ZhengDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.ORCID 0000-0002-8694-893X
Yixiao GuSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Wenying QiDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Wei WangDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Xiaoke LiDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Xiaobin ZaoDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Size LiDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Shaoyu LiuSujiatuo Township Community Health Service Center, Beijing, 100194, China.
Tianyu XueHebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, 050000, China.
Yongan YeDepartment of Spleen and Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100007, China.
Aimin LiuShangzhuang Township Community Health Service Center, Beijing, 100094, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs one of the common malignant tumors nowadays, liver cancer has more risk factors for its development and is characterized by a high recurrence rate, high mortality rate, and poor prognosis, which poses a great threat to people's health. The specific efficacy of traditional Chinese medicine is based on clinical practice, which is a high degree of generalization of the characteristics and scope of the clinical effects of prescription medicines and a special form of expression of the medical effects of the human body within the scope of traditional Chinese medicine. Because of its multi-ingredient, multi-target, and multi-pathway characteristics, it has a great advantage in the treatment of liver cancer. Still, at present, its specific molecular mechanism of action has not yet been clarified.

aimThis study reviews the current status and characteristics of network pharmacology research in the treatment of liver cancer, aiming to provide new ideas and methods for traditional Chinese medicine treatment of the disease.

methodsThis study was searched on the Web of Science and PubMed using keywords, such as "traditional Chinese medicine", "liver cancer," and "network pharmacology." The citation dates of the literature cited in this review are from 2000 to 2024.

resultsThe discovery of the key molecular mechanisms of traditional Chinese medicine in the treatment of liver cancer through the network pharmacology approach and the in-depth study of the related signaling pathways are conducive to a more in-depth exploration of traditional Chinese medicine.

conclusionNetwork pharmacology research plays a key role in the treatment and prevention of liver cancer and deserves deeper exploration in the future.

Indexed as

Antineoplastic Agents, PhytogenicDrugs, Chinese HerbalLiver NeoplasmsMedicine, Chinese TraditionalNetwork PharmacologyHumansAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalLiver cancerNetwork pharmacologyResearch progressTargets.Traditional Chinese medicine

Identifiers

PMID39806972
PMCPMC12728535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.